Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Tue Aug 18, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.29 (+2.83%)
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference Business Wire - Wed Aug 5, 7:00AM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates Business Wire - Mon Aug 3, 3:01PM CDT

– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027 – – Pre-NDA...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Prepares to Defend Its Pipeline Narrative, But Zorevunersen Data Timing Looms Large Barchart - Fri Jul 31, 4:08PM CDT

Barchart Research What to Expect from STOK Earnings STOK Generated July 31, 2026 Current Price $28.86 EPS Estimate $$-0.82 Consensus Rating Strong Buy Average Move 6.33% Stoke Therapeutics Prepares to...

STOK : 32.29 (+2.83%)
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates Business Wire - Mon Jul 27, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Thu Jul 16, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.29 (+2.83%)
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer Business Wire - Mon Jul 13, 6:30AM CDT

–Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases–

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Business Wire - Tue Jun 30, 7:00AM CDT

—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Tue Jun 16, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.29 (+2.83%)
Stoke Therapeutics to Present at Upcoming Investor Conferences in June Business Wire - Thu May 28, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.29 (+2.83%)
BIIB : 216.78 (+1.13%)

Barchart Exclusives

Microsoft vs. Broadcom: One Has 85% Upside, But I'm Picking the Other Barchart - Fri Aug 21, 6:00PM CDT
Wall Street sees 85% upside in Broadcom versus 45% for Microsoft. But bigger upside doesn't always mean the better buy. Here's why I'm sticking with Microsoft as the smarter AI stock for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.